VCM
TXG icon

Vigilant Capital Management’s 10x Genomics TXG Stock Holding History

Vigilant Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-197,440
Closed -$8.93M – 621
2022
Q2 		$8.93M Buy
197,440
+120,257
+156% +$6.24M 0.77% 45
2022
Q1 		$5.87M Buy
77,183
+5,946
+8% +$520K 0.45% 46
2021
Q4 		$10.6M Buy
71,237
+7,749
+12% +$1.19M 0.74% 46
2021
Q3 		$9.24M Buy
63,488
+1,461
+2% +$251K 0.74% 48
2021
Q2 		$12.1M Buy
62,027
+4,437
+8% +$803K 0.98% 46
2021
Q1 		$10.4M Buy
+57,590
New +$9.95M 0.93% 46

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vigilant Capital Management's TXG Position: Q3 2022 in Review

Vigilant Capital Management sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 197,440 shares — an estimated $8.93M sold.

Vigilant Capital Management first reported a position in TXG in Q1 2021 and held it in 6 quarters. The position peaked at $12.1M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Vigilant Capital Management reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Vigilant Capital Management sold 197,440 10x Genomics shares in Q3 2022, an estimated $8.93M.
  • Vigilant Capital Management first reported a position in 10x Genomics in Q1 2021 and held it in 6 quarters.
  • Vigilant Capital Management's 10x Genomics position peaked at $12.1M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Vigilant Capital Management's 13F filing for Q3 2022, filed 25 Oct 2022.